Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Brenus Pharma

Request full access

Off-the-shelf in vivo immunotherapy for hard-to-treat solid tumours

Clermont-Ferrand, FranceFounded 2014Biotech & Life Sciences

About Brenus Pharma

Brenus Pharma is a Lyon clinical-stage biotech developing off-the-shelf in vivo immunotherapy for hard-to-treat solid tumours. Its Stimulated Ghost Cells platform aims to make tumour antigens visible to the immune system without patient-specific cell manufacturing; lead candidate STC-1010 targets microsatellite-stable metastatic colorectal cancer and has FDA IND acceptance for Phase I. In July 2026 Brenus raised an €11 million ($12.6 million) Series A extension bringing total capital since inception to about €38 million, with follow-on from Angelor, UI Investissement, Crédit Agricole entities, Noshaq, Orsa, BIO JAG and Bpifrance (non-dilutive) plus new investors Sambrinvest and Korea Omega Investment Corp., after a €22.2 million Series A in 2024. Sources: EU-Startups 22 Jul 2026; company / BioSpace.

Source: Dealroom company data

At a glance

Status
Operational
Employees
25
Open positions
3
Dealroom signal
86.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Biotech and Pharma, EIT Health, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Horizon Europe, observatoire industrial tech, DT and LS
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jul 2026 $12M $48M Korea Omega Investment · Jaguar Biotech · Sambrinvest · Noshaq ↗
SERIES A✓Equity / VC Sep 2024 $24M $97M Orsa · Angelor · Noshaq ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Brenus Pharma website traffic

Latest recorded traffic for Brenus Pharma is 110 monthly website visits, down 90% over the last three months. Brenus Pharma's team grew 31.6% over the past year.

Latest monthly visits110 3-month web change-90% 1-year team growth+31.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Brenus Pharma in the Clermont-Ferrand ecosystem

Live from Dealroom

The Brenus Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Series A8 investors entered at this stage

  • Angelor
  • Orsa
  • Noshaq
  • Korea Omega Investment
  • Jaguar Biotech
  • Sambrinvest
  • Crédit Agricole
  • UI Investissement

Other known investors1 additional known investor

  • EIT Health
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Brenus Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.